Myeloma Paper of the Day, September 24th, suggested by Robert Orlowski

Robert Orlowski shared on X:

“Myeloma Paper of the Day: Pre-clinical in vitro data suggest CD38/CD3xCD28 trispecific T-cell engager (SAR442257) may work in patients after prior daratumumab. Interestingly, TCE lacking CD38-binding also worked, suggesting CD28 binding is enough.”

Source: Robert Orlowski/X

A CD38/CD3xCD28 trispecific T-cell engager as a potentially active agent in multiple myeloma patients relapsed and/or refractory to anti-CD38 monoclonal antibodies

Authors: Aintzane Zabaleta, Laura Blanco, Peter S. Kim, Kamlesh Bisht, Hongfang Wang, Helgi Van de Velde, Marta Lasa, Luis-Esteban Tamariz-Amador, Paula Rodriguez-Otero, Jesús San-Miguel, Bruno Paiva, Esperanza Martín-Sánchez.

Other posts featuring Robert Orlowski on OncoDaily.

Robert Orlowski, M.D., Ph.D., holds multiple positions at The University of Texas, MD Anderson Cancer Center including Chairman, Ad Interim Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics within the Division of Cancer Medicine. Additionally, he chairs the SWOG Barlogie/Salmon Myeloma Committee, which is part of the National Clinical Trials Network, dedicated to advancing new therapies and understanding the biology of myeloma.

Dr. Orlowski’s expertise lies in both clinical practice and scientific research, with a particular focus on translating laboratory discoveries into effective treatments for patients. He investigates drug resistance mechanisms in myeloma and seeks to identify predictive biomarkers for treatment response. Notably, his past contributions include leadership roles in developing proteasome inhibitors like bortezomib and carfilzomib, as well as monoclonal antibodies such as daratumumab and elotuzumab.